Adalimumab biosimilar - Samsung Bioepis

Drug Profile

Adalimumab biosimilar - Samsung Bioepis

Alternative Names: SB-5

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator Samsung Bioepis
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Rheumatoid arthritis

Most Recent Events

  • 11 Nov 2016 Updated efficacy and adverse events data from a phase III trial in Rheumatoid Arthritis presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2016)
  • 17 Jul 2016 Preregistration for Rheumatoid arthritis (In the elderly, In adults) in European Union (SC)
  • 09 Jun 2016 Efficacy and safety data from a phase III and phase I trial in Rheumatoid arthritis presented at the 17th Annual Congress of the European League Against Rheumatism (EULAR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top